|
|
Volumn 15, Issue 2, 2002, Pages 87-88
|
|
Editorial
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
ENDOSTATIN;
NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;
PRODRUG;
VASCULOTROPIN INHIBITOR;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTINEOPLASTIC ACTIVITY;
CANCER SCINTISCANNING;
CELL HYPOXIA;
CONTROLLED STUDY;
DIAGNOSTIC VALUE;
DRUG EFFICACY;
DRUG POTENTIATION;
DRUG RESISTANCE;
DRUG TARGETING;
EDITORIAL;
FEMALE;
FOLLOW UP;
GENETIC STABILITY;
HUMAN;
HUMAN TISSUE;
IMAGE ANALYSIS;
IMAGE ENHANCEMENT;
LUNG TUMOR;
METASTASIS;
NEOVASCULARIZATION (PATHOLOGY);
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
TUMOR CELL;
TUMOR VASCULARIZATION;
TUMOR VOLUME;
ANIMAL;
NEOPLASM;
VASCULARIZATION;
ANIMALIA;
ANGIOGENESIS INHIBITORS;
ANIMALS;
HUMANS;
MAGNETIC RESONANCE IMAGING;
NEOPLASMS;
|
|
EID: 0036195980
PISSN: 09523480
EISSN: None
Source Type: Journal
DOI: 10.1002/nbm.763 Document Type: Editorial |
|
Times cited : (5)
|
|
References (10)
|
